Globotriaosylceramide as a potential biomarker for auxiliary detection of lower respiratory tract infections of <em>Pseudomonas aeruginosa</em>

Xu,Tao; Li,Jiawei; Dong,Yuqing; Zhao,Zhijia; Yu,Li

doi:10.3892/etm.2025.12833

Globotriaosylceramide as a potential biomarker for auxiliary detection of lower respiratory tract infections of Pseudomonas aeruginosa

Authors:
- Tao Xu
- Jiawei Li
- Yuqing Dong
- Zhijia Zhao
- Li Yu
View Affiliations

Affiliations: Department of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, P.R. China, Department of Pulmonary and Critical Care Medicine, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang 315040, P.R. China, Department of Medical Records and Statistics, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang 315040, P.R. China
Published online on: February 24, 2025 https://doi.org/10.3892/etm.2025.12833
Article Number: 83
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lower respiratory tract infections (LRTIs) caused by Pseudomonas aeruginosa (PA) are a significant health concern, notably among vulnerable populations. The glycosphingolipid receptor globotriaosylceramide (Gb3) has been implicated in PA pathogenicity, however, its clinical implications remain underexplored. The present study aimed to investigate the clinical value of Gb3 concentrations in serum and bronchoalveolar lavage fluid (BALF) as a biomarker for PA‑induced LRTIs. In the current prospective study, 54 PA‑infected patients and 54 healthy individuals were enrolled as controls. Gb3 levels were measured using a Gb3 ELISA kit and the levels of inflammatory markers were assessed. The diagnostic accuracy of Gb3 was evaluated using receiver operating characteristic (ROC) curve analysis. The patients with PA‑induced LRTIs exhibited significantly higher Gb3 concentration levels in both serum and BALF compared with those noted in healthy controls, with more pronounced elevations noted in BALF. The area under the ROC curve was 0.899 for serum Gb3 and 0.812 for BALF Gb3, indicating high sensitivity and specificity for diagnosis of PA infection. Gb3 levels were also found to be correlated with C‑reactive protein and procalcitonin levels, suggesting its potential in reflecting infection severity. Overall, the present findings revealed a significant association between Gb3 levels and PA‑induced LRTIs, proposing Gb3 as a promising biomarker for early detection and diagnosis. Further research is warranted to validate the role of Gb3 in various patient populations and to explore its dynamics over the course of infection.

View Figures

View References

1	Crone S, Vives-Flórez M, Kvich L, Saunders AM, Malone M, Nicolaisen MH, Martínez-García E, Rojas-Acosta C, Catalina Gomez-Puerto M, Calum H, et al: The environmental occurrence of Pseudomonas aeruginosa. APMIS. 128:220–231. 2020.PubMed/NCBI View Article : Google Scholar
2	Berger C, Rückert C, Blom J, Rabaey K, Kalinowski J and Rosenbaum MA: Estimation of pathogenic potential of an environmental Pseudomonas aeruginosa isolate using comparative genomics. Sci Rep. 11(1370)2021.PubMed/NCBI View Article : Google Scholar
3	Diggle SP and Whiteley M: Corrigendum: Microbe profile: Pseudomonas aeruginosa: Opportunistic pathogen and lab rat. Microbiology (Reading). 167(001073)2021.PubMed/NCBI View Article : Google Scholar
4	Shi Y, Cao Q, Sun J, Hu X, Su Z, Xu Y, Zhang H, Lan L and Feng Y: The opportunistic pathogen Pseudomonas aeruginosa exploits bacterial biotin synthesis pathway to benefit its infectivity. PLoS Pathog. 19(e1011110)2023.PubMed/NCBI View Article : Google Scholar
5	Sathe N, Beech P, Croft L, Suphioglu C, Kapat A and Athan E: Pseudomonas aeruginosa: Infections and novel approaches to treatment ‘Knowing the enemy’ the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment. Infect Med (Beijing). 2:178–194. 2023.PubMed/NCBI View Article : Google Scholar
6	Zhang S and Stallforth P: Biofilms and exopolysaccharides in Pseudomonas aeruginosa: Pathogenesis, immune evasion, and lung-brain signaling during pneumonia. Signal Transduct Target Ther. 9(204)2024.PubMed/NCBI View Article : Google Scholar
7	Huang Q, Duan C, Ma H, Nong C, Zheng Q, Zhou J, Zhao N, Mou X, Liu T, Zou S, et al: Structural and functional characterization of itaconyl-CoA hydratase and citramalyl-CoA lyase involved in itaconate metabolism of Pseudomonas aeruginosa. Structure. 32:941–952.e3. 2024.PubMed/NCBI View Article : Google Scholar
8	Maruri-Aransolo A, López-Causapé C, Hernández-García M, García-Castillo M, Caballero-Pérez JD, Oliver A and Cantón R: In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain. J Antimicrob Chemother. 79:1432–1440. 2024.PubMed/NCBI View Article : Google Scholar
9	Ashworth EA, Wright RCT, Shears RK, Wong JKL, Hassan A, Hall JPJ, Kadioglu A and Fothergill JL: Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo. Nat Commun. 15(1547)2024.PubMed/NCBI View Article : Google Scholar
10	Siukstaite L, Imberty A and Römer W: Structural diversities of lectins binding to the glycosphingolipid Gb3. Front Mol Biosci. 8(704685)2021.PubMed/NCBI View Article : Google Scholar
11	Schubert T, Sych T, Madl J, Xu M, Omidvar R, Patalag LJ, Ries A, Kettelhoit K, Brandel A, Mely Y, et al: Differential recognition of lipid domains by two Gb3-binding lectins. Sci Rep. 10(9752)2020.PubMed/NCBI View Article : Google Scholar
12	Üçeyler N, Böttger J, Henkel L, Langjahr M, Mayer C, Nordbeck P, Wanner C and Sommer C: Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease. J Intern Med. 284:427–438. 2018.PubMed/NCBI View Article : Google Scholar
13	Dinu IR and Firu ŞG: Fabry disease-current data and therapeutic approaches. Rom J Morphol Embryol. 62:5–11. 2021.PubMed/NCBI View Article : Google Scholar
14	Bichet DG, Aerts JM, Auray-Blais C, Maruyama H, Mehta AB, Skuban N, Krusinska E and Schiffmann R: Assessment of plasma lyso-Gb₃ for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease. Genet Med. 23:192–201. 2021.PubMed/NCBI View Article : Google Scholar
15	Nowak A, Beuschlein F, Sivasubramaniam V, Kasper D and Warnock DG: Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J Med Genet. 59:287–293. 2022.PubMed/NCBI View Article : Google Scholar
16	Zhang T, de Waard AA, Wuhrer M and Spaapen RM: The Role of glycosphingolipids in immune cell functions. Front Immunol. 10(90)2019.PubMed/NCBI View Article : Google Scholar
17	Freedman SB, van de Kar N and Tarr PI: Shiga toxin-producing escherichia coli and the hemolytic-uremic syndrome. N Engl J Med. 389:1402–1414. 2023.PubMed/NCBI View Article : Google Scholar
18	Park JY, Kim CH and Cho SH: Glycan-adhering lectins and experimental evaluation of a lectin fimh inhibitor in enterohemorrhagic Escherichia coli (EHEC) O157:H7 strain EDL933. Int J Mol Sci. 23(9931)2022.PubMed/NCBI View Article : Google Scholar
19	Arenas-Mosquera D, Pinto A, Cerny N, Berdasco C, Cangelosi A, Geoghegan PA, Malchiodi EL, De Marzi M and Goldstein J: Cytokines expression from altered motor thalamus and behavior deficits following sublethal administration of Shiga toxin 2a involve the induction of the globotriaosylceramide receptor. Toxicon. 216:115–124. 2022.PubMed/NCBI View Article : Google Scholar
20	Zheng S, Eierhoff T, Aigal S, Brandel A, Thuenauer R, de Bentzmann S, Imberty A and Römer W: The Pseudomonas aeruginosa lectin LecA triggers host cell signalling by glycosphingolipid-dependent phosphorylation of the adaptor protein CrkII. Biochim Biophys Acta Mol Cell Res. 1864:1236–1245. 2017.PubMed/NCBI View Article : Google Scholar
21	Kociurzynski R, Makshakova ON, Knecht V and Römer W: Multiscale molecular dynamics studies reveal different modes of receptor clustering by Gb3-binding lectins. J Chem Theory Comput. 17:2488–2501. 2021.PubMed/NCBI View Article : Google Scholar
22	Feitz WJC, Bouwmeester R, van der Velden TJAM, Goorden S, Licht C, van den Heuvel LPJW and van de Kar NCAJ: The shiga toxin receptor globotriaosylceramide as therapeutic target in Shiga Toxin E. coli Mediated HUS. Microorganisms. 9(2157)2021.PubMed/NCBI View Article : Google Scholar
23	Brandel A, Aigal S, Lagies S, Schlimpert M, Meléndez AV, Xu M, Lehmann A, Hummel D, Fisch D, Madl J, et al: The Gb3-enriched CD59/flotillin plasma membrane domain regulates host cell invasion by Pseudomonas aeruginosa. Cell Mol Life Sci. 78:3637–3656. 2021.PubMed/NCBI View Article : Google Scholar
24	Gao S, Ni C, Huang W, Hao H, Jiang H, Lv Q, Zheng Y, Liu P, Kong D and Jiang Y: The interaction between flagellin and the glycosphingolipid Gb3 on host cells contributes to Bacillus cereus acute infection. Virulence. 11:769–780. 2020.PubMed/NCBI View Article : Google Scholar
25	Szymczak-Kulus K, Czerwinski M and Kaczmarek R: Human Gb3/CD77 synthase: A glycosyltransferase at the crossroads of immunohematology, toxicology, and cancer research. Cell Mol Biol Lett. 29(137)2024.PubMed/NCBI View Article : Google Scholar
26	Geyer PE, Maak M, Nitsche U, Perl M, Novotny A, Slotta-Huspenina J, Dransart E, Holtorf A, Johannes L and Janssen KP: Gastric adenocarcinomas express the glycosphingolipid Gb3/CD77: Targeting of gastric cancer cells with Shiga Toxin B-subunit. Mol Cancer Ther. 15:1008–1017. 2016.PubMed/NCBI View Article : Google Scholar
27	Pulmonary Infection Assembly of Chinese Thoracic Society. Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults (2022). Zhonghua Jie He He Hu Xi Za Zhi. 45:739–752. 2022.PubMed/NCBI View Article : Google Scholar : (In Chinese).
28	Sharma P, Zhang X, Ly K, Zhang Y, Hu Y, Ye AY, Hu J, Kim JH, Lou M, Wang C, et al: The lipid globotriaosylceramide promotes germinal center B cell responses and antiviral immunity. Science. 383(eadg0564)2024.PubMed/NCBI View Article : Google Scholar
29	Weinbergerova B, Kabut T, Kocmanova I, Lengerova M, Pospisil Z, Kral Z and Mayer J: Bronchoalveolar lavage fluid and serum 1,3-β-D-glucan testing for invasive pulmonary aspergillosis diagnosis in hematological patients: The role of factors affecting assay performance. Sci Rep. 10(17963)2020.PubMed/NCBI View Article : Google Scholar
30	Gan Q, Li Z, Li X, Huang Y and Deng H: Analysis of the effects of early screening combined with blood lactate on the severity of patients with sepsis. Heliyon. 10(e31907)2024.PubMed/NCBI View Article : Google Scholar
31	Formenti P, Gotti M, Palmieri F, Pastori S, Roccaforte V, Menozzi A, Galimberti A, Umbrello M, Sabbatini G and Pezzi A: Presepsin in critical illness: Current knowledge and future perspectives. Diagnostics (Basel). 14(1311)2024.PubMed/NCBI View Article : Google Scholar
32	Hu Y, Ren J, Lv Z, Liu H and Qiu X: Procalcitonin and C-reactive protein as early predictors in patients at high risk of colorectal anastomotic leakage. J Int Med Res. 52(3000605241258160)2024.PubMed/NCBI View Article : Google Scholar
33	Zeng Y, Xie Y, Chen D and Wang R: Related factors of euthyroid sick syndrome in patients with sepsis. Beijing Da Xue Xue Bao Yi Xue Ban. 56:526–532. 2024.PubMed/NCBI View Article : Google Scholar : (In Chinese).
34	Müller DC, Kauppi A, Edin A, Gylfe Å, Sjöstedt AB and Johansson A: Phospholipid levels in blood during community-acquired pneumonia. PLoS One. 14(e0216379)2019.PubMed/NCBI View Article : Google Scholar
35	Nan W, Xiong F, Zheng H, Li C, Lou C, Lei X, Wu H, Gao H and Li Y: Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia. Redox Boil. 58(102556)2022.PubMed/NCBI View Article : Google Scholar